[Complement inhibition: a new therapeutic modality?].
J M
JM
Porcel
D000328:Adult; D000818:Animals; D015703:Antigens, CD / Q000627:therapeutic use; D001550:Benzamidines; D001798:Blood Proteins / Q000627:therapeutic use; D018958:CD55 Antigens / Q000276:immunology; D018957:CD59 Antigens / Q000276:immunology; D002352:Carrier Proteins / Q000627:therapeutic use; D003167:Complement Activation; D003169:Complement Inactivator Proteins / Q000627:therapeutic use*; D015938:Complement Membrane Attack Complex / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology; D003327:Coronary Disease / Q000188:drug therapy; D003882:Dermatomyositis / Q000188:drug therapy; D004546:Elapid Venoms / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy / Q000276:immunology; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D051916:Membrane Cofactor Protein; D008562:Membrane Glycoproteins / Q000627:therapeutic use; D011951:Receptors, Complement / Q000276:immunology; D012128:Respiratory Distress Syndrome / Q000628:therapy; D012772:Shock, Septic / Q000628:therapy
D015703:Antigens, CD; D001550:Benzamidines; D001798:Blood Proteins; C497857:CD46 protein, human; D018958:CD55 Antigens; D018957:CD59 Antigens; D002352:Carrier Proteins; D003169:Complement Inactivator Proteins; D015938:Complement Membrane Attack Complex; D004546:Elapid Venoms; D006146:Guanidines; D016756:Immunoglobulins, Intravenous; D051916:Membrane Cofactor Protein; D008562:Membrane Glycoproteins; D011951:Receptors, Complement; C016310:cobra venom factor; C051590:CD59 protein, human; D003165:Complement System Proteins; C032855:nafamostat
Inhibición del complemento: una nueva modalidad terapéutica?